Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

University of Athens120 enrolled

Overview

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Light Transmission Aggregometry (LTAmax), as a marker of on-clopidogrel treatment platelet reactivity ii. Malondialdehyde (MDA), as oxidative stress marker, Mitochondrial-derived peptide MOTS-c and b-amyloid. blood levels.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Diabetes Clopidogrel Resistance Amyloid Insulin Resistance

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * type 2 diabetic patients with coronary artery disease, documented by coronary angiography, * both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study Exclusion Criteria: * abnormal renal function (creatinine\> 2.5 mg / dl), * hepatic failure (bilirubin\> 2 mg / dl), * active malignancy, * patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd, * patients with a history of hemorrhagic mood, * patients with thrombocytopenia (PLTs \< 100x109 / L) and * anemia (HCT \<28%).

Locations (1)

General & University Hospital "Attikon"

Chaïdári, Attica, Greece

Outcomes

Primary Outcomes

mots-c predicts cardiovascular mortality in diabetic with coronary artery disease

mots-c concentration in Diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality

Time frame: 2 year follow up

b amyloid predicts cardiovascular mortality in diabetic with coronary artery disease

b amyloid concentration in Diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality

Time frame: 2 year follow up

b amyloid predicts cardiovascular mortality in diabetic with coronary artery

Resistance to clopidogrel as defined by Light Transmission Aggregometry in diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality.

Time frame: 2 year follow up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.